Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.
Also called NCT07179380
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 344 participants
- Sponsor
- Registry
-
NCT07179380
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Colombia, Czechia, Denmark, France, Georgia, Germany, Greece, Israel, Italy, Japan, Malaysia, Mexico, New Zealand, Philippines, Poland, Portugal, Romania, Serbia, South Korea, Spain, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07179380. Randomized; double masking; primary purpose treatment. Start 2026-01-07 (actual); primary completion 2028-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Acronym
- PALM-ILD
- Condition
- Pulmonary Hypertension
- Condition
- Interstitial Lung Disease
- Intervention (Drug)
- Treprostinil Palmitil Inhalation Powder
- Intervention (Drug)
- Placebo
- Lead sponsor
- Insmed Incorporated
Record details
- Record id
cardio:ct-nct07179380- Content hash
ff460c2a5c543bc35381a270c24efd3424ce9e01bdc858fe80cec423b023389d